VectorBuilder Biotechnology (Guangzhou) Co., Ltd., a Hong Kong-based gene delivery company, raised CNY410M in Series C funding.
The round was led by Legend Capital.
The company intends to use the funds to promote the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.
Founded by Dr. Bruce Lahn, VectorBuilder provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine. The company has provided more than 1.2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies worldwide, and its gene-drug CRO and CDMO projects are spread all over North America, Europe, Japan and South Korea.
FinSMEs
20/10/2022